Halozyme Therapeutics (HALO) Treasury Shares (2010 - 2025)
Halozyme Therapeutics (HALO) posted quarterly Treasury Shares of $1.5 million for Q4 2025, up 215.48% year-over-year from $482403.0 in Q4 2024, and up 215.48% quarter-over-quarter from $482403.0 in Q4 2024.
Halozyme Therapeutics (HALO) Treasury Shares (2010 - 2025) Analysis & Trends
Halozyme Therapeutics (HALO) has reported Treasury Shares for 1 consecutive years, with $58.9 million the latest figure, recorded in Q3 2020.
- In Q4 2025, Treasury Shares rose 215.48% year-over-year to $1.5 million; the TTM figure through Dec 2025 stood at $1.5 million (up 215.48% YoY), while the FY2025 annual figure was $1.5 million, up 215.48% from the prior year.
- Treasury Shares advanced to $1.5 million in Q4 2025 per HALO's latest filing, from $482403.0 in the prior quarter.
- Across five years, Treasury Shares topped out at $1.5 million in Q4 2025 and bottomed at $482403.0 in Q4 2024.
- Historically, Treasury Shares has averaged $1.0 million across 5 years, with a median of $1.0 million in 2022.
- Annual changes were most pronounced in 2024 — Treasury Shares sank 57.66% — and 2025, when it jumped 215.48%.
- Halozyme Therapeutics' Treasury Shares stood at $858742.0 in 2021, then advanced by 21.04% to $1.0 million in 2022, then advanced by 9.62% to $1.1 million in 2023, then tumbled by 57.66% to $482403.0 in 2024, then surged by 215.48% to $1.5 million in 2025.
- Business Quant data shows HALO's Treasury Shares at $58.9 million in Q3 2020, $2.0 million in Q2 2020, and $51.6 million in Q1 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.08 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 92,219.00 |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.52 Mn |
| Dec 31, 2025 | 1.52 Mn |
| Dec 31, 2024 | 482,403.00 |
| Dec 31, 2024 | 482,403.00 |
| Dec 31, 2023 | 1.14 Mn |
| Dec 31, 2023 | 1.14 Mn |
| Dec 31, 2022 | 1.04 Mn |
| Dec 31, 2022 | 1.04 Mn |
| Dec 31, 2021 | 858,742.00 |
| Dec 31, 2021 | 858,742.00 |
| Dec 31, 2020 | 1.03 Mn |
| Dec 31, 2020 | 1.03 Mn |
| Sep 30, 2020 | 58.90 Mn |
| Sep 30, 2020 | 58.90 Mn |
| Jun 30, 2020 | 2.00 Mn |
| Jun 30, 2020 | 2.00 Mn |
| Mar 31, 2020 | 51.57 Mn |
| Mar 31, 2020 | 51.57 Mn |
| Dec 31, 2019 | 2.09 Mn |
| Dec 31, 2019 | 2.09 Mn |